The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats

References

• Aldridge MA, Ito MK. (2001). Fenofibrate and warfarin interaction. Pharmacotherapy 21:886–9
   PubMed Web of Science ®Google Scholar
• Anon. (2005). Warfarin interaction: interaction with fenofibrate leading to reduced warfarin requirement: case report. 23
   Google Scholar
• Asavapanumas N, Kittayaruksakul S, Meetam P, et al. (2012). Fenofibrate down-regulates renal OCT2-mediated organic cation transport via PPARα-independent pathways. Drug Metab Pharmacokinet 27:513–19
   PubMed Web of Science ®Google Scholar
• Ascah K, Rock G, Wells P. (1998). Interaction between fenofibrate and warfarin. Ann Pharmacother 32:765–8
   PubMed Web of Science ®Google Scholar
• Bonds DE, Craven TE, Buse J, et al. (2012). Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia 55:1641–50
   PubMed Web of Science ®Google Scholar
• Chan E, Mclachlana AJ, Rowlan M. (1994). Renal handling of warfarin metabolites in man. Eur J Pharm Sci 1:189–93
   Web of Science ®Google Scholar
• Daniel WA, Haduch A, Syrek M, Boksa J. (2006). Direct and indirect interactions between antidepressant drugs and CYP2C6 in the rat liver during long-term treatment. Eur Neuropsychopharmacol 16:580–7
   PubMed Web of Science ®Google Scholar
• Ding T, Zhang Y, Chen A, et al. (2015). Effects of cucurbitacin E, a tetracyclic triterpene compound from cucurbitaceae, on the pharmacokinetics and pharmacodynamics of warfarin in rats. Basic Clin Pharmacol Toxicol 116:385–9
   PubMed Web of Science ®Google Scholar
• Elsby R, Martin PD, Surry D, et al. (2015). Solitary inhibition of the breast cancer resistance protein (BCRP) efflux transporter results in a clinically significant drug-drug interaction with rosuvastatin by causing up to a two-fold increase in statin exposure. Drug Metab Dispos 44:398–408
   PubMed Web of Science ®Google Scholar
• Fasco MJ, Silkworth JB, Dunbar DA, Kaminsky LS. (1993). Rat small intestinal cytochromes P450 probed by warfarin metabolism. Mol Pharmacol 43:226–33
   PubMed Web of Science ®Google Scholar
• Forsblom C, Hiukka A, Leinonen ES, et al. (2010). Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care 33:215–20
   PubMed Web of Science ®Google Scholar
• Ghiculescu RA. (2006). Fenofibrate-warfarin interaction. Australian Prescriber 29:166
   Google Scholar
• Holford NH. (1986). Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet 11:483–504
   PubMed Web of Science ®Google Scholar
• Huang SM, Temple R, Throckmorton DC, Lesko LJ. FDA Guidance Page (2007). Draft guidance for industry: drug interaction studies—study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81:298–304
   PubMed Web of Science ®Google Scholar
• John J, John M, Wu L, et al. (2013). Effects of etravirine on the pharmacokinetics and pharmacodynamics of warfarin in rats. Br J Pharmacol 168:1851–8
   PubMed Web of Science ®Google Scholar
• Kaminsky LS, Zhang ZY. (1997). Human P450 metabolism of warfarin. Pharmacol Ther 73:67–74
   PubMed Web of Science ®Google Scholar
• Kim KY, Mancano MA. (2003). Fenofibrate potentiates warfarin effects. Ann Pharmacother 37:212–15
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Urashima K, Shimada N, Chiba K. (2002). Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem Pharmacol 63:889–96
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Florentin M, Elisaf MS. (2013). Fenofibrate and the kidney: an overview. Eur J Clin Investig 43:522–31
   PubMed Web of Science ®Google Scholar
• Kronbach T, Mathys D, Umeno M, et al. (1989). Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89–96
   PubMed Web of Science ®Google Scholar
• Leemann T, Transon C, Dayer P. (1993). Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52:29–34
   PubMed Web of Science ®Google Scholar
• Liu AC, Zhao LX, Yu SW, Lou HX. (2015). Pre-treatment with puerarin affects pharmacokinetics of warfarin, but not clopidogrel, in experimental rats. Chin J Nat Med 13:257–63
   Google Scholar
• Mychaleckyj JC, Craven T, Nayak U, et al. (2012). Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care 35:1008–14
   PubMed Web of Science ®Google Scholar
• Panossian A, Hovhannisyan A, Abrahamyan H, et al. (2009). Pharmacokinetic and pharmacodynamic study of interaction of Rhodiola rosea SHR-5 extract with warfarin and theophylline in rats. Phytother Res 23:351–7
   PubMed Web of Science ®Google Scholar
• Powell ML, Pope B, Elmer GW, Trager WF. (1977). Biliary excretion of warfarin metabolites and their metabolism by rat gut flora. Life Sci 20:171–7
   PubMed Web of Science ®Google Scholar
• Schelleman H, Han X, Brensinger CM, et al. (2014). Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol 78:639–48
   PubMed Web of Science ®Google Scholar
• Sugano S, Kobayashi T, Tanikawa T, et al. (2001). Suppression of CYP3A2 mRNA expression in the warfarin-resistant roof rat, Rattus rattus: possible involvement of cytochrome P450 in the warfarin resistance mechanism. Xenobiotica 31:399–407
   PubMed Web of Science ®Google Scholar
• Ufer M. (2005). Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 44:1227–46
   PubMed Web of Science ®Google Scholar
• Večeřa R, Zachařová A, Orolin J, et al. (2011). Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat. Biopharm Drug Dispos 32:482–7
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Li B, Louie SW, et al. (2005). Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 35:737–53
   PubMed Web of Science ®Google Scholar
• Yacobi A, Udall JA, Levy G. (1976). Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther 19:552–8
   PubMed Web of Science ®Google Scholar
• Zhang Z, Ge B, Zhou L, et al. (2014). Induction of liver cytochrome P450s by Danshen-Gegen formula is the leading cause for its pharmacokinetic interactions with warfarin. J Ethnopharmacol 154:672–86
   PubMed Web of Science ®Google Scholar
• Zhu X, Lee DY, Shin WG. (2007). Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. Biopharm Drug Dispos 28:125–33
   PubMed Web of Science ®Google Scholar